Upsher-Smith Laboratories in Plymouth to close, at least 58 employees to be laid off
Minnesota state officials announced that employees at Upsher-Smith Laboratories will be laid off after the company announced the closing of its facility in Plymouth.
Some employees at the Maple Grove facility will also be impacted by the layoffs, but that location will remain open.
The first phase of layoffs will be on April 4, while additional layoffs will be complete by July 31.
PLYMOUTH, Minn. (FOX 9) - About 58 employees with Upsher-Smith Laboratories, one of the oldest drug manufacturers in Minnesota, will be laid off.
This comes after the company announced its intention to close its facility in Plymouth, according to a Worker Adjustment and Retraining Notification (WARN) notice sent by the State Rapid Response Team on Thursday.
What's next
State officials say 58 employees will be impacted by the first phase of separations, which is set to happen on April 4.
The WARN notice states that subsequent phases will involve more layoffs, but the exact number has not yet been determined.
All phases, including the closing of Upsher-Smith's Plymouth facility, are expected to be complete by July 31, 2025.
What they're saying
The State Rapid Response Team said the affected employees are not represented by a union and that bumping rights do not exist.
The positions impacted include machinery and chemical technicians, maintenance planners, material handlers press operators and engineers.
The Source
A news release from the Minnesota Employment and Economic Development.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
05-08-2025
- Business Wire
Bora Pharmaceuticals Announces Multi-Year Expansion for Midwest Manufacturing Site, as Upsher-Smith Entity Split is Finalized
MAPLE GROVE, Minn.--(BUSINESS WIRE)-- Bora Pharmaceuticals Co., Ltd. ('Bora' or 'the Company', TWSE: 6472), a global leader in pharmaceutical manufacturing, has announced plans for significant investments to expand its manufacturing and packaging capabilities at its facility in Maple Grove, Minnesota. This is a major upgrade to the site, which Bora acquired in 2024 as part of its $210 million acquisition of Upsher-Smith Laboratories, expanding its U.S. manufacturing footprint. 'Bora's Maple Grove facility offers a unique opportunity for large pharmaceutical innovators to secure space in a state-of-the-art site staffed by experts in formulation development, tech transfer, and commercial manufacturing,' said J.D. Mowery. As the entity separation from Upsher-Smith Laboratories takes effect on August 5, Bora continues its growth amid surging demand for oral solid dose (OSD) development and manufacturing brought on by increasingly complex formulations, novel drug delivery technologies, and the growing shift of biologics into OSD formats. Bora has already secured multiple multi-million-dollar contracts for development and commercial supply of advanced OSD programs. 'With pharmaceutical companies relying more heavily on specialized CDMO partners to scale production and maintain quality, top-tier manufacturing capacity and technical expertise are at a premium,' said J.D. Mowery, president of Bora's CDMO business. 'Bora's Maple Grove facility offers a unique opportunity for innovators to secure space in a state-of-the-art site staffed by experts in formulation development, tech transfer, and commercial manufacturing.' The first phase of Bora's investment will add a Gerteis Macro-Pactor® at the company's state-of-the-art site. This investment initiates a broader buildout of 100,000 square feet of dedicated shell space designed to streamline production for partners with high-volume needs. The Gerteis Macro-Pactor® roller compactor will be installed and operational in the third quarter of 2025. 'As we complete our transition from Upsher-Smith, we're creating the infrastructure to deliver integrated manufacturing, packaging, and analytical services with the speed and quality our clients need,' shared Dennis Hall, Vice President and General Manager of the Maple Grove site. 'As we expand our capabilities, we look forward to tapping into all the experience and talent in the area.' The facility offers on-site quality control laboratories and a dedicated development team to support product and analytical development as well as innovation. It is an FDA-inspected manufacturing site and meets global health authority requirements, ensuring regulatory compliance. From early development and scale-up to process optimization and commercial manufacturing, Bora's experienced teams support customers at every stage of the product lifecycle. The company's commercial on-time, in-full (OTIF) delivery record is unmatched, reinforcing Bora's role as a trusted partner, supporting clients with secure, consistent supply. For more information, visit About Bora Pharmaceuticals Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products. From our world-class sites in North America and Asia, we deliver drug products with unparalleled quality to more than 100 markets around the world. For more information, visit
Yahoo
11-06-2025
- Yahoo
Wisconsin energy company to permanently close facility, 66 employees laid off
SAUKVILLE, Wis. (WFRV) – A Wisconsin company that provides energy solutions, including power generation and energy storage, has announced it will be closing its facility and laying off 66 employees. According to a Worker Adjustment and Retraining Notification (WARN) letter submitted to the Wisconsin Department of Workforce Development (DWD), Discover Energy, LLC, doing business under the name Rehlko (formerly known as Kohler Energy), is permanently closing its Saukville facility located at 300 N. Dekora Woods Blvd. Vehicle fire in Wisconsin controlled by sprinkler system, no one hurt Company officials said the facility is targeted to close by December 31, 2025, with layoffs occurring in three waves. Wave one will occur on or within 14 days of August 8, wave two on or within 14 days of September 5, and wave three on or within 14 days of December 31. The WARN letter states that the 66 employees being laid off are not represented by a union, and bumping rights do not apply. Bumping rights would allow senior employees to take over positions currently held by less senior employees, but this will not be the case in this instance. Terroristic threat charge being referred for Wisconsin 6th grader after email sent to middle school According to the DWD, this marks the third layoff notice in Wisconsin for the month of June. For more information on layoffs in Wisconsin, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
11-06-2025
- Yahoo
Independent pharmacies welcome legislation targeting drug middlemen
The Brief The legislation would create a single state-run pharmacy benefit manager to negotiate drug prices for Medicaid plans. Independent pharmacies often lose money on prescriptions because drug middlemen do not always reimburse them. The changes would take effect in 2027. (FOX 9) - Independent pharmacies applauded legislation that is awaiting the governor's signature, saying it would help them stay afloat as many of them struggle to survive. What we know Legislation awaiting Governor Tim Walz' signature would create a state-run pharmacy benefit manager, which would negotiate drug prices for Medicaid plans. The goal is to simplify the process, which now involves multiple pharmacy benefit managers, and increase transparency. The legislation would also require the state-run group to report prices, rebates and discounts to a state commissioner. Under the legislation, a single pharmacy benefit manager overseen by the state would be required to pay independent pharmacies for each prescription they fill. That requirement would take effect in 2027. In the meantime, the state would pay pharmacies a flat fee of $4.50 per prescription to keep them afloat. The backstory Pharmacy benefit managers, or PBMs, negotiate drug prices for insurance plans. Many of them are owned by insurance companies. Within the last year, the Federal Trade Commission has investigated pharmacy benefit managers. It released two scathing reports, accusing them of unfair business practices. What they're saying "You're paying the pharmacies better, pharmacies stay open, patients have choice where they get their care..." said pharmacist John Hoeschen, owner of St. Paul Corner Drug. "If you're losing $35, $40, $50, $55, $60, $70 dollars a prescription, what else can you sell to make that up? You can't. That's an unsustainable model. That is not a recipe for longevity in this business." Dig deeper Mark Cuban, the billionaire investor who has criticized pharmacy benefit managers and who started his own company to sell prescriptions at affordable rates, said the legislation in Minnesota does not do enough. In a post on X on Sunday, Cuban said "all it is doing is saying you want more details but keep doing business the way your PBMs always have.... They will just move things around to different places." What's next The legislation is awaiting the governor's signature.
